TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04319705
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin, 500mg, 3 times per week, 12-week treatment period, administered orally
Study: NCT04319705
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule containing placebo, 3 times per week, 12-week treatment period, administered orally
Study: NCT00312442
Drug: Treatment with WST09 Vascular Photodynamic therapy
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03023501
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02359968
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: radiochemotherapy before surgery
Study: NCT02961842
Drug: Intrathecal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 15 µg will be administered in the subarachnoid space
Study: NCT02961842
Drug: 500 mL Crystalloid Coload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
Study: NCT02961842
Drug: 1000 mL Crystalloid Coload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
Study: NCT04642989
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate standard-of-care antibiotics as determined by the physician.
Study: NCT03563222
Drug: Intralipid, 20%
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy.
Study: NCT03736967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC q2w
Study: NCT01490411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
Study: NCT00879190
Drug: Ampicillin/gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
Study: NCT01939054
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01539304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dry syrup, b.i.d
Study: NCT02634346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing
Study: NCT00605644
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00802425
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intratympanic injection
Study: NCT04446533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).
Study: NCT02573220
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02573220
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01458587
Drug: Aminolevulinic Acid PDT (ALA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Study: NCT00932256
Drug: STAHIST NDC #58407-536-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
Study: NCT02052362
Drug: ABT-450/r/ABT-267
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-450, ABT-267 and ritonavir
Study: NCT02453607
Drug: thiopurine
Normalized name: Thiopurine methyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
Study: NCT00977197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo will be administered twice a day
Study: NCT03758469
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
Study: NCT03248037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops
Study: NCT02650817
Drug: RAD1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD1901, a novel selective ER degrader (SERD)
Study: NCT00784693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV single dose
Study: NCT02968810
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01944423
Drug: Pill Placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02897349
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02897349
Drug: background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: insulin with or without metformin
Study: NCT00083915
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m2 continuous infusion days -3 and -2.
Study: NCT00586560
Drug: Kareniticin and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity.
Study: NCT02873234
Drug: Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
Study: NCT01235988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + standard of care
Study: NCT04771637
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is used to observe the effect on the electrophysiology and quality of recovery of the patients
Study: NCT01362257
Drug: Treatment Period 1 - IV dose of GSK573719
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of 65µg
Study: NCT03086213
Drug: Sulfentanyl
Normalized name: Sufentanyl
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anaesthetic
Study: NCT01932554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
Study: NCT01932554
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Scheduled ibuprofen,\~10 mg/kg every 6-8 hours
Study: NCT04011618
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
Study: NCT03794167
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 50mg/kg/day i.v. on days -3 and -2
Study: NCT03226236
Drug: High-Dose IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
Study: NCT03117036
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with curative intent
Study: NCT00731042
Drug: Avagard
Normalized name: Avagard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution, 6 mL, 6 applications/day for 14 days.
Study: NCT01482611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
Study: NCT01482611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
Study: NCT01482611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
Study: NCT01482611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
Study: NCT01939912
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiarrhythmic agent.
Study: NCT03265782
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
Study: NCT00731042
Drug: Purell Surgical Scrub
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution, 4 mL, 6 applications/day for 14 days.
Study: NCT01038063
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03248297
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin tablet
Study: NCT03248297
Drug: Azithromycin and amoxicillin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin and amoxicillin
Study: NCT03248297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT01267279
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid per protocol
Study: NCT03530293
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-active dosage form
Study: NCT00687934
Drug: STA-9090
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
Study: NCT03952065
Drug: PD1/PDL1/CTLA4 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of PD1/PDL1/CTLA4 inhibitors through peripheral vein or neck artery/intra-tumor.
Study: NCT04071080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mL Gatorade
Study: NCT01216033
Drug: 111-In-ABY-025
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of the agent
Study: NCT00244231
Drug: Nidadd
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00354393
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01886820
Drug: [18F]NAV4694
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01427387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02991885
Drug: HAL-MPE1 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous administrations of HAL-MPE1 placebo
Study: NCT03134157
Drug: oral drug and vaginal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
Study: NCT03134157
Drug: oral drug and oral placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
Study: NCT03134157
Drug: Vaginal placebo+ oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: prescription of Vaginal placebo + oral placebo every day for 3 months.
Study: NCT04259333
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib tablet
Study: NCT00523211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of placebo once daily.
Study: NCT04259333
Drug: Acetaminophen, Codeine Drug Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen-codeine-caffeine tablet
Study: NCT01561209
Drug: Amitryptiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitryptiline 5 mg before bedtime for 2 months
Study: NCT01561209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill~1 before bedtime
Study: NCT02529813
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03688295
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive antiobitherapy post surgery for CAA
Study: NCT01277861
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
Study: NCT03285178
Drug: IW-1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT02239211
Drug: BTT1023
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV (in the vein) Investigational Medicinal Product (IMP)
Study: NCT03285178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT03324685
Drug: BIIB074
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB074 is administered as specified in the treatment arm.
Study: NCT03324685
Drug: OC (ethinyl estradiol and levonorgestrel)
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC is administered as specified in the treatment arm.
Study: NCT01416038
Drug: low dose cyclophosphamide (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclophosphamide will be taken by mouth.
Study: NCT02016846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03609853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vapor (distilled water)
Study: NCT03609853
Drug: Vaporized THC, limonene, or THC and limonene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug exposure
Study: NCT01340820
Drug: AERAS-422
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBCG
Study: NCT01340820
Drug: BCG Tice
Normalized name: BCG TICE 50MG/AMP VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-8 x 10\^5 CFU
Study: NCT03645603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion
Study: NCT01084161
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo once per day
Study: NCT02265510
Drug: INCB039110
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
Study: NCT02340455
Drug: Placebo_Men
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo durg
Study: NCT02340455
Drug: Placebo_Women
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo_Women
Study: NCT01357772
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02763098
Drug: Remi 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Study: NCT02763098
Drug: Remi 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: .Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Study: NCT02915835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
Study: NCT02763098
Drug: Remi 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Study: NCT05732948
Drug: autologous T cells & cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of PD-1(programmed death 1)silent PSMA(prostate-specific membrane antigen)/PSCA(prostate stem cell antigen)targeted CAR-T administered one day after pretreatment with cyclophosphamide.
Study: NCT00523042
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target dose titration scheme, inhalation.
Study: NCT02623153
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine of 1000 mg/m2
Study: NCT03630341
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets identical to L-carnitine
Study: NCT01293461
Drug: CBX129801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT01293461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT01660126
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
Study: NCT01660126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no